Pfizer Advances Battle Against COVID-19 on Multiple Fronts
Pfizer Inc. today announced important advances in the battle against the global COVID-19 pandemic. As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem to address the COVID-19 global healthcare crisis.
Researchers and scientists have been relentlessly working to develop an investigational antiviral compound to treat SARS-CoV-2, which causes the current pandemic of coronavirus infections (COVID-19), a vaccine to prevent infection as well as evaluating other therapies that have scientific potential to help infected patients fight the virus.
Anti-Viral Compound Screening
Pfizer confirmed a lead compound and analogues are potent inhibitors of the SARS-CoV-2 3C-like (3CL) protease, based on the results of initial screening assays. In addition, preliminary data suggest the lead protease inhibitor shows antiviral activity against SARS-CoV-2. Consequently, Pfizer will perform pre-clinical confirmatory studies, including further anti-viral profiling and assessment of the suitability of the lead molecule for IV administration clinically. In parallel, the company is also investing in materials that will accelerate the start of a potential clinical study of the lead molecule to third quarter 2020, three or more months in advance of earlier estimates, subject to positive completion of the pre-clinical confirmatory studies.
Finalising Our Agreement with BioNTech
Pfizer Inc. and BioNTech SE have entered into a global collaboration agreement to co-develop BioNTech’s potential first-in-class, mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection. In March 2020, the companies announced a letter of intent to collaborate and began working together at that time. The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple research sites. BioNTech and Pfizer intend to initiate clinical trials as early as the end of April 2020, assuming regulatory clearance. The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval of regulatory authorities and then rapidly scale up to capacity to produce hundreds of millions of doses in 2021. Find out more.
Analysis of current agents with potential anti-viral properties
In an effort to share information that could benefit COVID-19 efforts, Pfizer researchers will publish our data regarding assets with potential antiviral properties.
Study partnership with Liverpool School of Tropical Medicine
Pfizer Inc. and the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group are launching two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2. Pfizer is expected to finalise in the coming days, a research collaboration agreement with Liverpool to provide funding and in-kind laboratory testing support for this research.
The studies (SAFER study (SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response) and the FASTER study (Facilitating A SARS CoV-2 Test for Rapid triage)) will help demonstrate whether patients infected with COVID-19 have a higher risk of also developing pneumococcal pneumonia and if having both infections leads to more severe disease and poorer outcomes. The SAFER study will enrol 100 healthcare workers at the Royal Liverpool Hospital and examine rates of SARS-CoV-2 acquisition and dynamics of pneumococcal colonisation. The FASTER study will recruit 400 patients from the infectious disease ward at the Royal Liverpool Hospital suspected of having coronavirus. Enrolment has already begun, and data are expected over the next few months.
Pfizer will continue to share information from its portfolio and emerging candidates that could benefit the many companies and organisations who are working quickly to provide solutions to combat this unprecedented healthcare crisis.
For all media enquiries, please contact:
Pfizer press office
Tel: 0845 300 8033
Email: [email protected]